Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 232 for “"HER-2"”.
-
HER-2/neu-targeted immunoprevention of breast cancer
… in the use of traditional breast cancer therapies have improved the overall survival of women with early stage disease. Remarkable advances in research have created a unique opportunity for developing active vaccination strategies that engage the body’s own immune system in the fight …
-
Πειραματικά μοντέλα ανοσοθεραπείας HER-2/neu θετικών όγκων
Overexpression of the HER-2/neu oncogene by a significant number of human carcinomas has been associated with more aggressive disease. Despite its high oncogenic potential, HER2/neu oncoprotein has been considered as a promising target for cancer therapeutics as it has been proven to be immunogenic …
-
HER-2/neu, Topoisomerase-II-α, Östrogen- und Progesteronrezeptor
… der Frau dar. Die Wahl der geeigneten Therapie wird für das metastasierte Mammakarzinom anhand des pathologisch untersuchten Gewebes des Primärtumors getroffen. Die Untersuchung der biologischen Marker von Fernund lokoregionären Lymphknotenmetastasen wird routinemäßig nicht durchgeführt. …
-
Ανοσοθεραπεία στον HER-2 θετικό καρκίνο του μαστού: Συστηματική ανασκόπηση
… είναι ο πιο συχνός καρκίνος στις γυναίκες. Ο HER-2 θετικός καρκίνος του μαστού είναι ένας επιθετικός υποτύπος. Παρά το γεγονός ότι οι αντι-HER2 θεραπείες έχουν βελτιώσει τη συνολική επιβίωση των ασθενών με μεταστατικό καρκίνο του μαστού με μέσο όρο άνω των 5 ετών, υπάρχει ανάγκη για ακόμα …
-
Παραγωγή κυτταροτοξικών κυττάρων γενετικά τροποποιημένων ώστε να αναγνωρίζουν την HER-2/neu ογκοπρωτεΐνη, μέσω χιμαιρικών υποδοχέων: Πειραματικά μοντέλα θεραπείας HER-2/neu θετικών χειρουργημένων όγκων
The HER-2/neu proto-oncogene is overexpressed in a variety of human cancers and this is correlated with increased malignancy and poor prognosis. HER-2/neu is an immunogenic protein because it contains epitopes which are recognized by T cells in a MHC class I and class II restricted fashion. However …
-
HER-2/neu Genamplifikation und Rezeptorüberexpression in verschiedenen Tumoren des Ovars
Die vorgelegte Arbeit beschäftigt sich mit der Her-2/neu Genamplifikation und der Her-2/neu Rezeptorüberexpression in verschiedenen Tumoren des Ovars. Untersucht wurden diese Veränderungen mit der Fluoreszenz-in situ-Hybridisierung und der Immunhistochemie. Die Ergebnisse bei den Ovarialkarzinomen …
-
Proteomics analysis of Her-2/neu-linked protein profiles in tumor microenvironment
… proteomics had been employed to analyze the HER-2/neu-linked protein profiles in breast tumor microenvironment. Proteome profiles of the HER-2/neu-positive and -negative breast tumors were generated with two-dimensional gel electrophoresis. Combinations of different pH ranges of IPG …
-
Novel targeted agents in Her-2 positive and triple negative breast cancer
The development of Her-2 targeted therapies has improved the prognosis for patients with Her-2 positive breast cancer. However, not all Her-2 positive tumours respond to treatment with Her-2 antagonists. Triple negative cancers are resistant to hormone and Her-2 targeted therapies. This project …
-
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
… promising effectors for tumor adoptive immunotherapy, particularly when considering the targeting of MHC class I low or negative tumors. Yet, many tumor cells are resistant to NK killing, which is mainly the case for non-hematopoietic tumors such as carcinomas or melanoma, even when these cells …
-
Bedeutung des Her-2/neu beim Ovarialkarzinom - Korrelation und Vergleich mit klinischen Prognosefaktoren
… wird eine immunhistochemische Bestimmung des Her-2/neu - Status vorgenommen, der beim Mamma-Karzinom als unabhängiger Prognosefaktor bekannt ist und mit einer schlechteren Prognose einhergeht. Zusammenfassend ließ sich in dieser Arbeit keine Überexpression des Her-2/neu am Ovar feststellen, …
-
Evidencia sobre la expresión de Her-2 en la enfermedad de Paget Extramamaria
… potential to produce metastasis and even death. HER2 is a biomarker that is currently under study due to its clinical implications in the diagnosis, evolution and prognosis of the disease. The present study proposes to identify the evidence related to the behavior of this biomarker in …
-
Expressão imuno-histoquímica das proteínas VEGF e HER-2 em biópsias de osteossarcoma
… encontrado geralmente em jovens. VEGF e HER-2 têm sido utilizados em diversos tipos de tumores como possíveis marcadores de imuno-histoquímica relacionados ao prognóstico; no entanto, estudos realizados em osteossarcomas ainda apresentam resultados contraditórios. Objetivos: Identificar a …
-
Expressão de HER-2/neu e p53 em adenocarcinoma de esôfago e cárdia
… de estudos da patogênese destes tumores. HER-2/neu é um oncogene expresso in diversas neoplasias e relacionado à pior prognóstico. P53 é igualmente importante estando mutado em 50%-70% das neoplasias sólidas com implicações clínicas para muitos tumores. Este trabalho determina a frequência …
-
Her-2/3 heterodimers : a quantitative molecular epidemiology marker and method of analysis
Thesis (M.S.)--Michigan State University. Department of Epidemiology, 2001
-
The role of EGFR, HER 2-4, heregulin and downstream signalling in prostate adenocarcinoma
… Currently evidence regarding influence of the HER tyrosine kinase family - EGFR, HER2, HER3 and HER4 - during disease progression in prostate adenocarcinoma is conflicting – both poor prognosis and no influence on outcome are reported. A small cohort pilot study of paired hormone sensitive …
-
Topoisomerase ll-a e Her-2 em tumores malignos de mama e de ovário
Introdução. O receptor epidérmico humano 2 (Her-2) e a topoisomerase-IIα (T2A) são dois marcadores biológicos importantes, ambos tendo um valor prognóstico e preditivo potencial em pacientes com tumores sólidos. A amplificação dos genes Her- 2 e T2A são eventos independentes, embora o último seja …
-
Ανάπτυξη και αξιολόγηση συστημάτων χορήγησης πεπτιδικών αντιγόνων HER-2/neu συνδεδεμένων με PLA μικροσφαίρες
Despite the progress of classic therapeutic strategies developed concerning cancer the greatest number of patients deteriorates and eventually dies. The need to confront this disease in an alternative way has led to the development of new immunotherapeutic methods. The identification of …
Page 1 of 12